Zimberelimab
- Generic Name
- Zimberelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2259860-24-5
- Unique Ingredient Identifier
- ZBL7O904IL
- Indication
用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤（r/r cHL）患者。
- Associated Conditions
- -
- Associated Therapies
- -
Study of Novel Treatment Combination Therapies in Participants with Head and Neck Squamous Cell Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT06727565
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 154
- Registration Number
- NCT06532565
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
- Conditions
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 129
- Registration Number
- NCT06431633
- Locations
- 🇪🇸
Hospital General de Elche, Elche, Alicante, Spain
🇪🇸ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 31
- Registration Number
- NCT06238921
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT06166589
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT06155396
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳Beijing Obstetrics and Gynecology Hospital ,Capital Medical University, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-08-29
- Target Recruit Count
- 70
- Registration Number
- NCT06133517
- Locations
- 🇪🇸
ICO Badalona, Badalona, Barcelona, Spain
🇪🇸Hospital Duran i Reynals (ICO L´Hospitalet), L'Hospitalet De Llobregat, Barcelona, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-30
- Target Recruit Count
- 24
- Registration Number
- NCT06128460
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06120075
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States
🇺🇸Georgtown, Washington, District of Columbia, United States
Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Xuekui Liu
- Target Recruit Count
- 52
- Registration Number
- NCT06107114
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.